JP Morgan Comments on Potential Combination Of Valeant And Zoetis, Remains Overweight VRX and Neutral on ZTS

The bank sees Zoetis as an 'attractive, durable, cash-pay business to Valeant's portfolio' and that a deal would be minimal accretive to EPS in the next 12 months. However, the deal would bring benefits in the longer run by aiding multiple expansion. Synergies remain elusive to those trying to identify them